Xeris' GVOKE (glucagon) Receives FDA's Approval as The First Ready-To-Use Stable Liquid Glucagon for Severe Hypoglycemia
Shots:
- The approval is based on three P-III studies (NCT02656069- NCT03091673- NCT03439072) assessing GVOKE vs conventional glucagon emergency kits in adults and children aged ≥2yrs. with T1D
- The studies demonstrated 100% treatment success in children & 99% in adults. Usability research assessing GVOKE PFS and GVOKE HypoPen resulted in ~100% success rate in administering a full dose of glucagon utilizing 2-step administration process
- GVOKE is the first premixed- prefilled- premeasured liquid glucagon administered via prefilled syringe (GVOKE PFS) or auto-injector (GVOKE HypoPen) in patients with severe hypoglycemic events and will be available in 0.5 mg/0.1 mL dose and a 1 mg/0.2 mL dose for pediatric and adolescent/adult patients respectively
Click here to read full press release/ article | Ref: Xeris Pharmaceutical | Image: Xeris Pharmaceutical
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
